New Narcolepsy Tool Captures Full Functional Burden Beyond Daytime Sleepiness
The FINI instrument measures six key life domains in narcolepsy patients, offering clinicians a richer picture than sleepiness scales alone.
Summary
Researchers developed the Functional Impacts of Narcolepsy Instrument (FINI), a new patient-reported outcome measure designed to capture the broad functional burden of narcolepsy types 1 and 2. Unlike existing tools that focus mainly on excessive daytime sleepiness, FINI measures six domains: Tiredness, Cognitive Functioning, Cataplexy, Social Activities, Everyday Activities, and Everyday Responsibilities. The NT1 version contains 28 items; the NT2 version excludes the Cataplexy domain and contains 23 items. Development involved patient interviews, input from sleep clinicians and outcomes scientists, and rigorous statistical validation including exploratory and confirmatory factor analyses plus Rasch analysis. The result is a validated, comprehensive tool that better reflects how narcolepsy disrupts patients' daily lives, supporting both clinical care and drug development outcomes measurement.
Detailed Summary
Narcolepsy is a chronic neurological disorder that disrupts sleep-wake regulation, but its impact extends well beyond excessive daytime sleepiness. Patients commonly experience cataplexy, cognitive difficulties, fatigue, and impaired social and occupational functioning — dimensions that most existing outcome measures fail to capture systematically. This gap limits both clinical assessment and the evaluation of new treatments in trials.
To address this, researchers at Takeda Development Center Americas and collaborating institutions developed the Functional Impacts of Narcolepsy Instrument (FINI), a novel patient-reported outcome measure validated separately for narcolepsy type 1 (NT1) and type 2 (NT2). The development process was rigorous and multi-stage, beginning with patient experience interviews to identify meaningful impacts, followed by item development drawing on both original content and the established PROMIS library, two rounds of patient debriefing interviews, and advanced psychometric analyses including exploratory factor analysis, Rasch analysis, and confirmatory factor analysis.
The final FINI for NT1 comprises 28 items across six independent domains: Tiredness, Cognitive Functioning, Cataplexy, Social Activities, Everyday Activities, and Everyday Responsibilities — all assessed over a 7-day recall period. The NT2 version contains 23 items across five domains, excluding Cataplexy, which is not a feature of NT2. Statistical analyses and consensus meetings with expert clinicians confirmed good content validity for both versions.
For clinicians and researchers, the FINI fills a meaningful gap in narcolepsy care. It enables more comprehensive monitoring of how the disease affects patients' real-world functioning, supports shared decision-making, and provides a robust endpoint for clinical trials evaluating narcolepsy therapies.
Caveats include the instrument's industry sponsorship (Takeda), which warrants attention to potential bias. Additionally, long-term test-retest reliability, responsiveness to treatment change, and performance across diverse real-world populations remain to be established in future studies.
Key Findings
- FINI covers six functional domains in NT1: Tiredness, Cognitive Functioning, Cataplexy, Social Activities, Everyday Activities, and Everyday Responsibilities.
- NT2 version contains 23 items across five domains, omitting the Cataplexy subscale not relevant to NT2.
- Development combined patient interviews, PROMIS items, and rigorous factor and Rasch analyses to confirm validity.
- A 7-day recall period was selected to balance accuracy with meaningful symptom capture.
- FINI adds a validated, multi-domain outcome tool to the limited assessment toolkit for central hypersomnolence disorders.
Methodology
The FINI was developed through a multi-stage process including patient experience interviews, item generation, two waves of patient debriefing, and psychometric validation using exploratory factor analysis, Rasch analysis, and confirmatory factor analysis. Separate instruments were created for NT1 and NT2 populations with input from sleep medicine experts and clinical outcomes scientists. Consensus meetings finalized the item set and domain structure.
Study Limitations
This summary is based on the abstract only, as the full text is not open access. The instrument was developed with pharmaceutical industry sponsorship (Takeda), which may introduce bias. Psychometric properties such as test-retest reliability, sensitivity to treatment change, and cross-cultural validity in diverse populations have not yet been reported.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.